TY - JOUR
TI - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
AU - Richter, J.
AU - Lübking, A.
AU - Söderlund, S.
AU - Lotfi, K.
AU - Markevärn, B.
AU - Själander, A.
AU - Stenke, L.
AU - Deneberg, S.
AU - Ahlstrand, E.
AU - Myhr-Eriksson, K.
AU - Panayiotidis, P.
AU - Gedde-Dahl, T.
AU - Žáčková, D.
AU - Mayer, J.
AU - Olsson-Strömberg, U.
AU - Mahon, F.-X.
AU - Saussele, S.
AU - Hjorth-Hansen, H.
AU - Koskenvesa, P.
JO - Leukemia Research
PY - 2021
VL - 35
TODO - 8
SP - 2416-2418
PB - Springer Nature BV
SN - 0145-2126
TODO - 10.1038/s41375-021-01173-w
TODO - BCR ABL protein;  BCR ABL1 protein;  protein tyrosine kinase inhibitor;  unclassified drug;  BCR ABL protein;  protein kinase inhibitor, Article;  cancer patient;  cause of death;  chronic myeloid leukemia;  clinical practice;  drug withdrawal;  follow up;  human;  incidence;  leukemia relapse;  leukemia remission;  mismatch repair;  molecular genetics;  molecular pathology;  outcome assessment;  patient monitoring;  prediction;  real time polymerase chain reaction;  stem cell transplantation;  treatment duration;  chronic myeloid leukemia;  clinical trial (topic);  diagnosis;  epidemiology;  Europe;  genetics;  pathology;  procedures;  prognosis;  remission;  time factor;  treatment withdrawal;  tumor recurrence, Clinical Trials as Topic;  Europe;  Fusion Proteins, bcr-abl;  Humans;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Neoplasm Recurrence, Local;  Prognosis;  Protein Kinase Inhibitors;  Remission Induction;  Time Factors;  Withholding Treatment
TODO - null
ER -